Strategic partnerships Leverage VeonGen's proprietary retinal gene therapy platform VG801 for co-development or licensing opportunities with larger ophthalmology players and contract research organizations focusing on ABCA4-related diseases, potentially accelerating clinical milestones and market access.

Regulatory momentum Capitalize on FDA Regenerative Medicine Advanced Therapy designation and FDA Rare Disease Endpoint Advancement collaboration to position potential investors and partners around expedited development timelines, favorable regulatory dialogue, and potential fast-track pathways.

Clinical leadership Engage with academic and nonprofit networks connected to Stargardt and ABCA4-related retinal dystrophies to identify research collaborations, patient registries, and trial sites, expanding trial feasibility and patient recruitment channels.

Market expansion Explore cross-indication opportunities with other ABCA4-related or retinal dystrophy conditions and adjacent ocular diseases where a dual AAV vector approach could be adaptable, broadening the potential addressable market.

Funding and visibility Position VeonGen for strategic financing and partnership deals by highlighting ongoing ARVO presentations, upcoming clinical milestones, and FDA collaborations to attract pharma/biotech interest and potential co-development or milestone-based funding.